These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 21828264)

  • 1. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
    J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.
    Uchida Y; Wakayama K; Ohtsuki S; Chiba M; Ohe T; Ishii Y; Terasaki T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):578-88. PubMed ID: 24947467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
    Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
    Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
    Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
    Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models.
    Uchida Y; Ohtsuki S; Terasaki T
    Drug Metab Dispos; 2014 Oct; 42(10):1719-26. PubMed ID: 25061162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Targeted Absolute Proteomics of Transporters and Pharmacoproteomics-Based Reconstruction of P-Glycoprotein Function in Mouse Small Intestine.
    Akazawa T; Uchida Y; Tachikawa M; Ohtsuki S; Terasaki T
    Mol Pharm; 2016 Jul; 13(7):2443-56. PubMed ID: 27276518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
    Ose A; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Fujita T; Yamamoto A; Sugiyama Y
    Drug Metab Dispos; 2008 Feb; 36(2):427-34. PubMed ID: 18039806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.
    Yamazaki M; Neway WE; Ohe T; Chen I; Rowe JF; Hochman JH; Chiba M; Lin JH
    J Pharmacol Exp Ther; 2001 Mar; 296(3):723-35. PubMed ID: 11181899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
    Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.
    Takeuchi T; Yoshitomi S; Higuchi T; Ikemoto K; Niwa S; Ebihara T; Katoh M; Yokoi T; Asahi S
    Pharm Res; 2006 Jul; 23(7):1460-72. PubMed ID: 16779700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport.
    Katoh M; Suzuyama N; Takeuchi T; Yoshitomi S; Asahi S; Yokoi T
    J Pharm Sci; 2006 Dec; 95(12):2673-83. PubMed ID: 16892207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
    de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the cassette-dosing approach to assess brain penetration in drug discovery.
    Liu X; Ding X; Deshmukh G; Liederer BM; Hop CE
    Drug Metab Dispos; 2012 May; 40(5):963-9. PubMed ID: 22328585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse.
    Booth-Genthe CL; Louie SW; Carlini EJ; Li B; Leake BF; Eisenhandler R; Hochman JH; Mei Q; Kim RB; Rushmore TH; Yamazaki M
    J Pharmacol Toxicol Methods; 2006; 54(1):78-89. PubMed ID: 16545584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios.
    Kalvass JC; Maurer TS; Pollack GM
    Drug Metab Dispos; 2007 Apr; 35(4):660-6. PubMed ID: 17237155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
    Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
    Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug.
    Jonker JW; Wagenaar E; van Deemter L; Gottschlich R; Bender HM; Dasenbrock J; Schinkel AH
    Br J Pharmacol; 1999 May; 127(1):43-50. PubMed ID: 10369454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.